Skip to main navigation
Skip to search
Skip to main content
Karl Landsteiner University of Health Sciences Home
Help & FAQ
English
Deutsch
Home
Profiles
Research units
Projects
Research output
Activities
Prizes
Press/Media
Search by expertise, name or affiliation
Functional analysis of JunB-mediated immunosuppression
Podar, Klaus
(PI)
Division of Internal Medicine 2 (University Hospital Krems)
Overview
Fingerprint
Research output
(1)
Project Details
Status
Finished
Effective start/end date
01.10.2019
→
30.09.2020
Funding
Forschungsimpulse
View all
View less
Keywords
Multiple myeloma
immune checkpoint inhibition
AP-1 transcription factor JunB
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
Protein Kinase Inhibitor
Pharmacology, Toxicology and Pharmaceutical Science
100%
Multiple Myeloma
Pharmacology, Toxicology and Pharmaceutical Science
100%
Aurora Kinase
Pharmacology, Toxicology and Pharmaceutical Science
16%
Phosphotransferase Inhibitor
Pharmacology, Toxicology and Pharmaceutical Science
16%
Survival
Pharmacology, Toxicology and Pharmaceutical Science
16%
Cyclin Dependent Kinase
Pharmacology, Toxicology and Pharmaceutical Science
16%
Neoplasm
Pharmacology, Toxicology and Pharmaceutical Science
16%
Imatinib
Pharmacology, Toxicology and Pharmaceutical Science
16%
Research output
Research output per year
2019
2019
2019
1
Review article
Research output per year
Research output per year
Emerging protein kinase inhibitors for the treatment of multiple myeloma
Lind, J.
,
Czernilofsky, F.
,
Vallet, S.
&
Podar, K.
,
03 Jul 2019
,
In:
Expert Opinion on Emerging Drugs.
24
,
3
,
p. 133-152
20 p.
Research output
:
Journal article (peer-reviewed)
›
Review article
Multiple Myeloma
100%
Protein Kinase Inhibitor
100%
Neoplasm
16%
Aurora Kinase
16%
Protein Tyrosine Kinase
16%
22
Citations (Scopus)